Retired Medtronic Chair CEO Bill Hawkins [Photo courtesy of Biogen]
“Every life sciences CEO I speak to is trying to understand how to use AI to accelerate safe innovation,” Hawkins said in a statement shared with Medical Design & Outsourcing ahead of the announcement. “Companies want AI throughout development, in compliance workflows, and increasingly inside the products themselves, but most don’t have the infrastructure needed to use it safely, and at scale, in a regulated environment. This is one of the most important problems to solve, and it’s the reason I’ve decided to join Ketryx’s board.”
He later continued, “Technology evolution has brought forward AI that is enabling companies to accelerate the development of new products critical for improving the human condition. What impressed me about Ketryx was how they envisioned using AI to build safer products faster. That change will unlock the next decade of medicine, and it runs on infrastructure that didn’t exist until now.”
More from Ketryx: Three strategies for unlocking the power of continuous integration/continuous deployment (CI/CD) for AI-powered medical devices
Ketryx says its agentic continuous compliance platform is used by four of the world’s top five medical device manufacturers. The artificial-intelligence-powered platform automates compliance documentation and traceability and enabled “safe and verifiable AI at scale in the tools teams already use,” Ketryx says.
The platform reduces documentation time, strengthens quality processes, and helps companies prepare for regulatory submissions without disrupting modern development workflows, Ketryx says.
Ketryx co-founder and CEO Erez Kaminski [Photo courtesy of Ketryx]
Ketryx landed Hawkins as an investor in 2025 through its $39 million Series B funding round.
More from Ketryx: Three steps for traceability in medical device software development quality and compliance
